Article citationsMore>>

Kaley, T.J., Panageas, K.S., Pentsova, E.I., et al. (2020) Phase I Clinical Trial of Temsirolimus and Perifosine for Recurrent Glioblastoma. Annals of Clinical and Translational Neurology, 7, 429-436.
https://doi.org/10.1002/acn3.51009

has been cited by the following article:

• TITLE: An Immunogenic Cell Death-Related Classification Predicts Prognosis and Response to Immunotherapy in Glioblastoma

  AUTHORS: Xiaobin Luo

  KEYWORDS: Immunogenic Cell Death, Prognostic Value, Classification, Immunotherapy, Glioblastoma

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.8, August 18, 2023

  ABSTRACT: To investigate the immunogenic Cell Death gene’s potential mechanism and prognostic value in glioblastoma. Information on GBM samples from The Cancer Genome Atlas database was downloaded, ICD genes were obtained, genotyping, integrated bioinformatics to verify the prognostic value of genotyping, and finally, prognostic model construction. Two subtypes associated with the ICD gene were obtained by consensus clustering, and the high ICD subtype (risk) group was associated with poor prognosis, high mutations in the PTEN gene, high stromal score, and high immune score. We also constructed a new classification system for GBM based on ICD characteristics. This study is the first to use immunogenic cell death genes for genotyping and successfully build a prognostic model.